Αποτελέσματα Αναζήτησης
25 Νοε 2019 · FRANKFURT/LONDON (Reuters) - European private equity firm CapVest has tapped potential bidders for its French nuclear medicine provider Curium, sources told Reuters, aiming for a deal that values...
1 Ιαν 2021 · Information on valuation, funding, acquisitions, investors, and executives for Curium Pharma (Paris). Use the PitchBook Platform to explore the full profile.
Legal NameCurium Holding France S.A.S. Company TypeFor Profit. Phone Number+33 1 69 85 76 76. Curium is a world-class nuclear medicine solutions provider with over 100 years of industry experience.
See Curium funding rounds, investors, investments, exits and more. Evaluate their financials based on Curium's post-money valuation and revenue.
6 Απρ 2017 · IBA Molecular was created in 2012 following the buy-out of the radiopharmaceutical division of Ion Beam Applications (“IBA”) SA, a European-based leader in advanced cancer radiation therapy which is listed on the Euronext pan-European Stock Exchange. In 2016, IBA Molecular was acquired by CapVest.
9 Ιαν 2020 · January 9, 2020. CVC Capital Partners, Bain Capital, Clayton Dubilier & Rice, Nordic Capital and PAI Partners have submitted first-round bids to acquire Curium Pharma from CapVest in a deal that would value the company at $3 billion or more, according to Bloomberg.
Curium is a Missouri-based pharmaceutical company that manufactures and distributes nuclear medicine and radiopharmaceutical products for the healthcare industry. Curium’s primary competitors include Advanced Accelerator Applications, Lantheus, Bracco and 13 more.
